Exclusive Summary

• Demonstrated Best-in-Class potential for Thymic Carcinoma with a Median Overall Survival (mOS) of 31.07 months in pivotal Phase II trials, outperforming historical data for Keytruda (24.9 months).
• Backed by the largest clinical trial sample size (69 patients) for this rare indication globally, featuring a superior safety profile with a discontinuation rate due to drug-related AEs of only 7.2%.
• Solid global foundation with IND approvals in both China and the US, valid molecular patents in the EU and US, and mature CMC (Process Validation completed), making it a de-risked asset ready for licensing.

Asset Materials

Contact Us for Full Materials